In vivo selection to identify bacterial strains with enhanced ecological performance in synbiotic applications

Applied and Environmental Microbiology

Volumn 81, Issue 7, 2015, Pages 2455-2465

  Krumbeck, Janina A ^a,b   Maldonado Gomez, María X ^a   Martínez, Inés ^a,d   Frese, Steven A ^a,e   Burkey, Thomas E ^a   Rasineni, Karuna ^c   Ramer Tait, Amanda E ^a   Harris, Edward N ^a   Hutkins, Robert W ^a   Walter, Jens ^a,d  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^b UNIVERSITY OF NEBRASKA   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYMERASE CHAIN REACTION; RATS; RNA;

16S RRNA SEQUENCING; BIFIDOBACTERIUM ADOLESCENTIS; ECOLOGICAL PERFORMANCE; GALACTO-OLIGOSACCHARIDES; GASTROINTESTINAL TRACT; PROBIOTIC BACTERIA; QUANTITATIVE REAL TIME PCR; RETROSPECTIVE ANALYSIS;

BACTERIA;

COMPETITION (ECOLOGY); FECES; MICROBIAL ACTIVITY; POLYMERASE CHAIN REACTION; PROBIOTICS; RNA; SYMBIOSIS; SYNERGISM;

BACTERIA (MICROORGANISMS); BIFIDOBACTERIUM; BIFIDOBACTERIUM ADOLESCENTIS; RATTUS;

BACTERIAL DNA; RIBOSOME DNA; RNA 16S; SYNBIOTIC AGENT;

ANIMAL; BIFIDOBACTERIUM; CHEMISTRY; DNA SEQUENCE; DRUG EFFECTS; FECES; GENETIC SELECTION; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; MOLECULAR GENETICS; RAT; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; BIFIDOBACTERIUM; DNA, BACTERIAL; DNA, RIBOSOMAL; FECES; HUMANS; MOLECULAR SEQUENCE DATA; RATS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, RIBOSOMAL, 16S; SELECTION, GENETIC; SEQUENCE ANALYSIS, DNA; SYNBIOTICS;

EID: 84925372749     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.03903-14     Document Type: Article

References (75)

1. Hildebrand F, Nguyen TLA, Brinkman B, Yunta RG, Cauwe B, Vandenabeele P, Liston A, Raes J. 2013. Inflammation-associated enterotypes, host genotype, cage and inter-individual effects drive gut microbiota variation in common laboratory mice. Genome Biol 14:R4. http://dx.doi.org/10.1186/gb-2013-14-1-r4.
2. Lee DK, Park SY, An HM, Kim JR, Kim MJ, Lee SW, Cha MK, Kim SA, Chung MJ, Lee KO, Ha NJ. 2011. Antimicrobial activity of Bifidobacterium spp. isolated from healthy adult Koreans against cariogenic microflora. Arch Oral Biol 56:1047-1054. http://dx.doi.org/10.1016/j.archoralbio.2011.03.002.
3. Clemente JC, Ursell LK, Parfrey LW, Knight R. 2012. The impact of the gut microbiota on human health: an integrative view. Cell 148:1258-1270. http://dx.doi.org/10.1016/j.cell.2012.01.035.
4. Round JL, Mazmanian SK. 2009. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 9:313-323. http://dx.doi.org/10.1038/nri2515.
5. Tlaskalová-Hogenová H, Stěpánková R, Kozáková H, Hudcovic T, Vannucci L, Tučková L, Rossmann P, Hrnčíř T, Kverka M, Zákostelská Z, Klimešová K, Přibylová J, Bártová J, Sanchez D, Fundová P, Borovská D, Srùtková D, Zídek Z, Schwarzer M, Drastich P, Funda DP. 2011. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol 8:110-120. http://dx.doi.org/10.1038 /cmi.2010.67.
6. Cani PD, Delzenne NM. 2009. Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota. Curr Opin Pharmacol 9:737-743. http://dx.doi.org/10.1016/j.coph.2009.06.016.
7. Hooper LV, Littman DR, Macpherson AJ. 2012. Interactions between the microbiota and the immune system. Science 336:1268-1273. http://dx.doi.org/10.1126/science.1223490.
8. Walker AW, Lawley TD. 2013. Therapeutic modulation of intestinal dysbiosis. Pharmacol Res 69:75-86. http://dx.doi.org/10.1016/j.phrs.2012.09.008.
9. Frank DN, Pace NR. 2008. Gastrointestinal microbiology enters the metagenomics era. Curr Opin Gastroenterol 24:4-10. http://dx.doi.org/10.1097/MOG.0b013e3282f2b0e8.
10. Al-Sheraji SH, Ismail A, Manap MY, Mustafa S, Yusof RM, Hassan FA. 2013. Prebiotics as functional foods: a review. J Funct Foods 5:1542-1553. http://dx.doi.org/10.1016/j.jff.2013.08.009.
11. Gibson GR, Roberfroid MB. 1995. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 125: 1401-1412.
12. Tuohy KM, Probert HM, Smejkal CW, Gibson GR. 2003. Using probiotics and prebiotics to improve gut health. Drug Discov Today 8:692-700. http://dx.doi.org/10.1016/S1359-6446(03)02746-6.
13. Hooda S, Boler BMV, Serao MCR, Brulc JM, Staeger MA, Boileau TW, Dowd SE, Fahey GC, Jr, Swanson KS. 2012. 454 pyrosequencing reveals a shift in fecal microbiota of healthy adult men consuming polydextrose or soluble corn fiber. J Nutr 142:1259-1265. http://dx.doi.org/10.3945/jn.112.158766.
14. Martínez I, Kim J, Duffy PR, Schlegel VL, Walter J. 2010. Resistant starches types 2 and 4 have differential effects on the composition of the fecal microbiota in human subjects. PLoS One 5:e15046. http://dx.doi.org /10.1371/journal.pone.0015046.
15. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME. 2014. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11:506-514. http://dx.doi.org/10.1038/nrgastro.2014.66.
16. Kolida S, Gibson GR. 2011. Synbiotics in health and disease. Annu Rev Food Sci Technol 2:373-393. http://dx.doi.org/10.1146/annurev-food-022510-133739.
17. Tanaka R, Takayama H, Morotomi M, Kuroshima T, Ueyama S, Matsumoto K, Kuroda A, Masahiko M. 1983. Effects of administration of TOS and Bifidobacterium breve 4006 on the human fecal flora. Bifidobact Microflora 2:17-24. http://dx.doi.org/10.12938/bifidus1982.2.1_17.
18. Ogawa T, Asai Y, Yasuda K, Sakamoto H. 2005. Oral immunoadjuvant activity of a new synbiotic Lactobacillus casei subsp casei in conjunction with dextran in BALB/c mice. Nutr Res 25:295-304. http://dx.doi.org/10.1016/j.nutres.2004.10.012.
19. Ogawa T, Asai Y, Tamai R, Makimura Y, Sakamoto H, Hashikawa S, Yasuda K. 2006. Natural killer cell activities of synbiotic Lactobacillus casei ssp. casei in conjunction with dextran. Clin Exp Immunol 143:103-109. http://dx.doi.org/10.1111/j.1365-2249.2005.02975.x.
20. Rabiu BA, Jay AJ, Gibson GR, Rastall RA. 2001. Synthesis and fermentation properties of novel galacto-oligosaccharides by beta-galactosidases from Bifidobacterium species. Appl Environ Microbiol 67:2526-2530. http://dx.doi.org/10.1128/AEM.67.6.2526-2530.2001.
21. Modesto M, D'Aimmo MR, Stefanini I, Trevisi P, De Filippi S, Casini L, Mazzoni M, Bosi P, Biavati B. 2009. A novel strategy to select Bifidobacterium strains and prebiotics as natural growth promoters in newly weaned pigs. Livest Sci 122:248-258. http://dx.doi.org/10.1016/j.livsci.2008.08.017.
22. Malinen E, Mättö J, Salmitie M, Alander M, Saarela M, Palva A. 2002. Analysis of Bifidobacterium populations in human faecal samples from a consumption trial with Bifidobacterium lactis Bb-12 and a galactooligosaccharide preparation. Syst Appl Microbiol 25:249-258. http://dx.doi.org/10.1078/0723-2020-00117.
23. Alander M, Mättö J, Kneifel W, Johansson M, Koegle B, Crittenden R, Mattila-Sandholm T, Saarela M. 2001. Effect of galacto-oligosaccharide supplementation on human faecal microflora and on survival and persistence of Bifidobacterium lactis Bb-12 in the gastrointestinal tract. Int Dairy J 11:817-825. http://dx.doi.org/10.1016/S0958-6946(01)00100-5.
24. Rattanaprasert M, Roos S, Hutkins RW, Walter J. 2014. Quantitative evaluation of synbiotic strategies to improve persistence and metabolic activity of Lactobacillus reuteri DSM 17938 in the human gastrointestinal tract. J Funct Foods 10:85-94. http://dx.doi.org/10.1016/j.jff.2014.05.017.
25. Davis LMG, Martínez I, Walter J, Hutkins R. 2010. A dose dependent impact of prebiotic galactooligosaccharides on the intestinal microbiota of healthy adults. Int J Food Microbiol 144:285-292. http://dx.doi.org/10.1016/j.ijfoodmicro.2010.10.007.
26. Martínez I, Wallace G, Zhang C, Legge R, Benson AK, Carr TP, Moriyama EN, Walter J. 2009. Diet-induced metabolic improvements in a hamster model of hypercholesterolemia are strongly linked to alterations of the gut microbiota. Appl Environ Microbiol 75:4175-4184. http://dx.doi.org/10.1128/AEM.00380-09.
27. Rozen S, Skaletsky H. 2000. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132:365-386.
28. Ahmed U, Redgrave TG, Oates PS. 2009. Effect of dietary fat to produce non-alcoholic fatty liver in the rat. J Gastroenterol Hepatol 24:1463-1471. http://dx.doi.org/10.1111/j.1440-1746.2009.05870.x.
29. Folch J, Lees M, Sloan Stanely G. 1957. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226:497-509.
30. Simental-Mendía LE, Rodríguez-Hernández H, Rodríguez-Morán M, Guerrero-Romero F. 2012. The alanine aminotransferase to triglycerides ratio as a marker to identify nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 24:1173-1177. http://dx.doi.org/10.1097/MEG.0b013e32 83564ee5.
31. Lee J-T, Pao L-H, Lee M-S, Liao J-W, Shih C-M, Hsiong C-H, Yin F-Y, Shih T-Y, Hu OY-P. 2013. A new approach to facilitate diagnosis of nonalcoholic fatty liver disease through a galactose single point method in rats with fatty liver. Dig Liver Dis 45:134-141. http://dx.doi.org/10.1016 /j.dld.2012.08.019.
32. Davis LMG, Martínez I, Walter J, Goin C, Hutkins RW. 2011. Barcoded pyrosequencing reveals that consumption of galactooligosaccharides results in a highly specific bifidogenic response in humans. PLoS One 6:e25200. http://dx.doi.org/10.1371/journal.pone.0025200.
33. Ito M, Deguchi Y, Miyamori A, Matsumoto K, Kikuchi H, Kobayashi Y, Yajima T, Kan T. 1990. Effects of administration of galactooligosaccharides on the human faecal microflora, stool weight and abdominal sensation. Microb Ecol Health Dis 3:285-292. http://dx.doi.org/10.3109 /08910609009140251.
34. Gibson GR. 1999. Dietary modulation of the human gut microflora using the prebiotics oligofructose and inulin. J Nutr 129:1438-1441.
35. Sako T, Matsumoto K, Tanaka R. 1999. Recent progress on research and applications of non-digestible galacto-oligosaccharides. Int Dairy J 9:69-80. http://dx.doi.org/10.1016/S0958-6946(99)00046-1.
36. Macfarlane S, Macfarlane GT, Cummings JH. 2006. Review article: prebiotics in the gastrointestinal tract. Aliment Pharmacol Ther 24:701-714. http://dx.doi.org/10.1111/j.1365-2036.2006.03042.x.
37. Silk DBA, Davis A, Vulevic J, Tzortzis G, Gibson GR. 2009. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 29: 508-518. http://dx.doi.org/10.1111/j.1365-2036.2008.03911.x.
38. Ben X-M. 2008. Low level of galacto-oligosaccharide in infant formula stimulates growth of intestinal Bifidobacteria and Lactobacilli. World J Gastroenterol 14:6564-6568. http://dx.doi.org/10.3748/wjg.14.6564.
39. Chen J, Wang R, Li X-F, Wang R-L. 2012. Bifidobacterium adolescentis supplementation ameliorates visceral fat accumulation and insulin sensitivity in an experimental model of the metabolic syndrome. Br J Nutr 107:1429-1434. http://dx.doi.org/10.1017/S0007114511004491.
40. Reichold A, Brenner SA, Spruss A, Förster-Fromme K, Bergheim I, Bischoff SC. 2014. Bifidobacterium adolescentis protects from the development of nonalcoholic steatohepatitis in a mouse model. J Nutr Biochem 25:118-125. http://dx.doi.org/10.1016/j.jnutbio.2013.09.011.
41. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, Gibson GR, Delzenne NM. 2007. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50:2374-2383. http://dx.doi.org/10.1007/s00125-007-0791-0.
42. Everard A, Lazarevic V, Gaïa N, Johansson M, Ståhlman M, Backhed F, Delzenne NM, Schrenzel J, François P, Cani PD. 2014. Microbiome of prebiotic-treated mice reveals novel targets involved in host response during obesity. ISME J 8:2116-2130. http://dx.doi.org/10.1038/ismej.2014.45.
43. Cani PD, Delzenne NM, Amar J, Burcelin R. 2008. Role of gut microflora in the development of obesity and insulin resistance following highfat diet feeding. Pathol Biol 56:305-309. http://dx.doi.org/10.1016/j.patbio.2007.09.008.
44. Liong MT, Shah NP. 2006. Effects of a Lactobacillus casei synbiotic on serum lipoprotein, intestinal microflora, and organic acids in rats. J Dairy Sci 89: 1390-1399. http://dx.doi.org/10.3168/jds.S0022-0302(06)72207-X.
45. Yang S-C, Chen J-Y, Shang H-F, Cheng T-Y, Tsou SC, Chen J-R. 2005. Effect of synbiotics on intestinal microflora and digestive enzyme activities in rats. World J Gastroenterol 11:7413-7417. http://dx.doi.org/10.3748 /wjg.v11.i47.7413.
46. Le Leu RK, Brown IL, Hu Y, Bird AR, Jackson M, Esterman A, Young GP. 2005. A synbiotic combination of resistant starch and Bifidobacterium lactis facilitates apoptotic deletion of carcinogen-damaged cells in rat colon. J Nutr 135:996-1001.
47. Igarashi M, Liyama Y, Kato R, Tomita M, Asami N. 1994. Effect of Bifidobacterium longum and lactulose on the strength of bone in ovariectomized osteoporosis model rats. Bifidus 7:139-147.
48. Bielecka M, Biedrzycka E, Majkowska A. 2002. Selection of probiotics and prebiotics for synbiotics and confirmation of their in vivo effectiveness. Food Res Int 35:125-131. http://dx.doi.org/10.1016/S0963-9969 (01)00173-9.
49. Bomhof MR, Saha DC, Reid DT, Paul HA, Reimer RA. 2014. Combined effects of oligofructose and Bifidobacterium animalis on gut microbiota and glycemia in obese rats. Obesity 22:763-771. http://dx.doi.org/10.1002 /oby.20632.
50. Frece J, Kos B, Svetec IK, Zgaga Z, Beganović J, Lebos A, Susković J. 2009. Synbiotic effect of Lactobacillus helveticus M92 and prebiotics on the intestinal microflora and immune system of mice. J Dairy Res 76:98-104. http://dx.doi.org/10.1017/S0022029908003737.
51. Foye OT, Huang I-F, Chiou CC, Walker WA, Shi HN. 2012. Early administration of probiotic Lactobacillus acidophilus and/or prebiotic inulin attenuates pathogen-mediated intestinal inflammation and Smad 7 cell signaling. FEMS Immunol Med Microbiol 65:467-480. http://dx.doi.org/10.1111/j.1574-695X.2012.00978.x.
52. Ogawa T, Hashikawa S, Asai Y, Sakamoto H, Yasuda K, Makimura Y. 2006. A new synbiotic, Lactobacillus casei subsp. casei together with dextran, reduces murine and human allergic reaction. FEMS Immunol Med Microbiol 46:400-409. http://dx.doi.org/10.1111/j.1574-695X.2006.00046.x.
53. Piva A, Casadei G, Gatta PP, Luchansky JB, Biagi G. 2005. Effect of lactitol, lactic acid bacteria, or their combinations (synbiotic) on intestinal proteolysis in vitro, and on feed efficiency in weaned pigs. Can J Anim Sci 85:345-353. http://dx.doi.org/10.4141/A04-087.
54. Bird AR, Vuaran M, Crittenden R, Hayakawa T, Playne MJ, Brown IL, Topping DL. 2009. Comparative effects of a high-amylose starch and a fructooligosaccharide on fecal bifidobacteria numbers and short-chain fatty acids in pigs fed Bifidobacterium animalis. Dig Dis Sci 54:947-954. http://dx.doi.org/10.1007/s10620-008-0451-3.
55. Böhmer BM, Branner GR, Roth-Maier DA. 2005. Precaecal and faecal digestibility of inulin (DP 10-12) or an inulin/Enterococcus faecium mix and effects on nutrient digestibility and microbial gut flora. J Anim Physiol Anim Nutr (Berl) 89:388-396. http://dx.doi.org/10.1111/j.1439-0396.2005.00530.x.
56. Bomba A, Nemcová R, Gancarcíková S, Herich R, Guba P, Mudronová D. 2002. Improvement of the probiotic effect of micro-organisms by their combination with maltodextrins, fructo-oligosaccharides and polyunsaturated fatty acids. Br J Nutr 88(Suppl 1):S95-S99. http://dx.doi.org/10.1079/BJN2002634.
57. Shim SB, Verstegen MWA, Kim IH, Kwon OS, Verdonk JMAJ. 2005. Effects of feeding antibiotic-free creep feed supplemented with oligofructose, probiotics or synbiotics to suckling piglets increases the preweaning weight gain and composition of intestinal microbiota. Arch Anim Nutr 59:419-427. http://dx.doi.org/10.1080/17450390500353234.
58. Baffoni L, Gaggìa F, Di Gioia D, Santini C, Mogna L, Biavati B. 2012. A Bifidobacterium-based synbiotic product to reduce the transmission of C. jejuni along the poultry food chain. Int J Food Microbiol 157:156-161. http://dx.doi.org/10.1016/j.ijfoodmicro.2012.04.024.
59. Abdel-Raheem S, Abd-Allah S, Hassanein K. 2012. The effects of prebiotic, probiotic and synbiotic supplementation on intestinal microbial ecology and histomorphology of broiler chickens. Int J Agro Vet Med Sci 6:277-289. http://dx.doi.org/10.5455/ijavms.156.
60. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O'Neil DA, Macfarlane GT. 2005. Synbiotic therapy (Bifidobacterium longum/ Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 54:242-249. http://dx.doi.org/10.1136/gut.2004.044834.
61. Gopal PK, Prasad J, Gill HS. 2003. Effects of the consumption of Bifidobacterium lactis HN019 (DR10) and galacto-oligosaccharides on the microflora of the gastrointestinal tract in human subjects. Nutr Res 23:1313-1328. http://dx.doi.org/10.1016/S0271-5317(03)00134-9.
62. Schultz M, Munro K, Tannock GW, Melchner I, Göttl C, Schwietz H, Schölmerich J, Rath HC. 2004. Effects of feeding a probiotic preparation (SIM) containing inulin on the severity of colitis and on the composition of the intestinal microflora in HLA-B27 transgenic rats. Clin Diagn Lab Immunol 11:581-587. http://dx.doi.org/10.1128/CDLI.11.3.581-587.2004.
63. Nakanishi S, Kataoka K, Kuwahara T, Ohnishi Y. 2003. Effects of high amylose maize starch and Clostridium butyricum on metabolism in colonic microbiota and formation of azoxymethane-induced aberrant crypt foci in the rat colon. Microbiol Immunol 47:951-958. http://dx.doi.org/10.1111/j.1348-0421.2003.tb03469.x.
64. Krause DO, Bhandari SK, House JD, Nyachoti CM. 2010. Response of nursery pigs to a synbiotic preparation of starch and an anti-Escherichia coli K88 probiotic. Appl Environ Microbiol 76:8192-8200. http://dx.doi.org/10.1128/AEM.01427-10.
65. Stecher B, Hardt W-D. 2008. The role of microbiota in infectious disease. Trends Microbiol 16:107-114. http://dx.doi.org/10.1016/j.tim.2007.12.008.
66. Kalliomäki M, Collado MC, Salminen S, Isolauri E. 2008. Early differences in fecal microbiota composition in children may predict overweight. Am J Clin Nutr 87:534-538.
67. Ewaschuk JB, Diaz H, Meddings L, Diederichs B, Dmytrash A, Backer J, Looijer-van Langen M, Madsen KL. 2008. Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function.Am J Physiol Gastrointest Liver Physiol 295:G1025-G1034. http://dx.doi.org /10.1152/ajpgi.90227.2008.
68. Wang Z, Xiao G, Yao Y, Guo S, Lu K, Sheng Z. 2006. The role of bifidobacteria in gut barrier function after thermal injury in rats. J Trauma 61:650-657. http://dx.doi.org/10.1097/01.ta.0000196574.70614.27.
69. Mitsuoka T. 1990. Bifidobacteria and their role in human health. J Ind Microbiol 6:263-267. http://dx.doi.org/10.1007/BF01575871.
70. Petrof EO, Khoruts A. 2014. From stool transplants to next-generation microbiota therapeutics. Gastroenterology 146:1573-1582. http://dx.doi.org/10.1053/j.gastro.2014.01.004.
71. Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K, Tobe T, Clarke JM, Topping DL, Suzuki T, Taylor TD, Itoh K, Kikuchi J, Morita H, Hattori M, Ohno H. 2011. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469: 543-547. http://dx.doi.org/10.1038/nature09646.
72. Maathuis AJH, van den Heuvel EG, Schoterman MHC, Venema K. 2012. Galacto-oligosaccharides have prebiotic activity in a dynamic in vitro colon model using a (13)C-labeling technique. J Nutr 142:1205-1212. http://dx.doi.org/10.3945/jn.111.157420.
73. Liu C, Finegold SM, Song Y, Lawson PA. 2008. Reclassification of Clostridium coccoides, Ruminococcus hansenii, Ruminococcus hydrogenotrophicus, Ruminococcus luti, Ruminococcus productus and Ruminococcus schinkii as Blautia coccoides gen. nov., comb. nov., Blautia hansenii comb. nov., Blautia hydroge. Int J Syst Evol Microbiol 58:1896-1902. http://dx.doi.org/10.1099/ijs.0.65208-0.
74. De Vuyst L, Leroy F. 2011. Cross-feeding between bifidobacteria and butyrate-producing colon bacteria explains bifdobacterial competitiveness, butyrate production, and gas production. Int J Food Microbiol 149: 73-80. http://dx.doi.org/10.1016/j.ijfoodmicro.2011.03.003.
75. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, de Vos WM, Cani PD. 2013. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A 110: 9066-9071. http://dx.doi.org/10.1073/pnas.1219451110.